BTX1801 kills highly contagious, common living organisms that...

BTX1801 kills highly contagious, common living organisms that cause disability, infertility, and death. It is worth developing for sure, but is it worth it for BOT to develop it? To develop it, you’d be doing it only to sell it. If it doesn’t work out, all that money is gone. Look at Brickell, US$160mil to develop SB and they sold it for what.. 10% of that?!

For a BP they would look at BTX1801 not only for what they can sell the product for, but as a way to retain patients in their other drug revenue streams. For instance, a patient with kidney disease that develops a staph infection has a 20-50% chance of dying within a week. So you swab their nose every month, say you make $20 a swab, $240 a year, but that patient isn’t only on drugs for their kidney disease, but diabetes, high blood pressure etc. So by preventing say 3,000 deaths from sepsis in kidney patients per year you’re selling 3,000 more lots each month of each other drug they take. That’s where the value is for BTX1801 IMO.